NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
64 hedge funds and large institutions have $18.4M invested in NeuBase Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 11 closing their positions.
193% more call options, than puts
Call options by funds: $2.55M | Put options by funds: $871K
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
21% more funds holding
Funds holding: 53 → 64 (+11)
64% less capital invested
Capital invested by funds: $50.6M → $18.4M (-$32.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$14.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.06M |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$2.36M |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$1.69M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$8.62M |
| 2 |
Millennium Management
New York
|
-$5.95M |
| 3 |
VM
VHCP Management
New York
|
-$3.98M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$3.78M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.08M |
NBSE Hedge Fund Activity: Q1 2015 in Review
64 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2015, worth a combined $18.4M — down 64% from $50.6M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new NBSE positions and 11 closed out — a net gain of 12 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $14.7M. The largest seller was Visium Asset Management, exiting entirely with an estimated $8.62M sold.
- 64 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2015, up from 53 in Q4 2014.
- Funds reported $18.4M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2015, down 64% quarter-over-quarter.
- 23 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2015 and 11 closed out, a net change of +12 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2015 was Broadfin Capital, an estimated $14.7M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2015 was Visium Asset Management, an estimated $8.62M sold.
Based on aggregated 13F filings for Q1 2015.